Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Companies Support Telehealth Reforms – But Seek Demo Projects First

This article was originally published in The Gray Sheet

Executive Summary

Responding to a chronic care reform effort by the Senate Finance Committee, AdvaMed, device firms and several medical groups asked for demo projects and waivers to appropriately expand the use of telehealth services.

You may also be interested in...

Chronic-Care Bill Would Extend Pilot On Use Of Home-Care Devices, Promote Telehealth

Democratic and Republican leaders of the Senate Finance Committee plan to reintroduce the Chronic Care Act in 2017. It would provide Medicare pay incentives to improve management of chronic-care patients at home, streamline care coordination, and promote telehealth opportunities.

Senate Draft Chronic-Care Bill Seeks To Expand Telehealth Opportunities

The US Senate Finance Committee circulated a discussion draft of a chronic-care bill Oct. 27 that would promote telehealth and home-use devices. The bill would allow reimbursement for providers to use technology to monitor patients with chronic diseases through telehealth options in Medicare Advantage plans and accountable-care organizations.

CEOs Want Anti-Kickback, Self-Referral Law Waivers For ACO Interactions

The Healthcare Leadership Council – a coalition of health care CEOs – wants Congress to allow more waivers for accountable care organizations from the anti-kickback statute and the Stark law, which protects against physician self-referrals, and are also pushing the same slate of device regulatory reforms as in the House-approved 21st Century Cures bill.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts